Table 2

ACR responses, DAS28 C-reactive protein, and EULAR28 responses at week 24

AMG 108


Placebo

(n = 203)

50 mg

(n = 204)

125 mg

(n = 203)

250 mg

(n = 203)


ACR response, n (%)a

ACR20

59 (29.1)

63 (30.9) (P = 0.746)

73 (36.0) (P = 0.168)

82 (40.4) (P = 0.022)

ACR50

17 (8.4)

24 (11.8) (P = 0.323)

28 (13.8) (P = 0.113)

41 (20.2) (P < 0.001)

ACR70

8 (3.9)

4 (2.0) (P = 0.259)

5 (2.5) (P = 0.575)

12 (5.9) (P = 0.492)

DAS28 CRP, mean change from baselineb

-0.60

-0.69 (P = 0.213)

-0.92 (P < 0.001)

-1.18 (P < 0.001)

EULAR28 response, n (%)c

Good

16 (8%)

20 (10%)

28 (13.9%)

39 (19.5%)

Moderate

61 (30.7%)

59 (29.3%)

76 (37.8%)

76 (38%)

No response

122 (61.3%)

122 (60.7%)

97 (48.3%)

85 (42.5%)


ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, Disease Activity Score (28-joint count); EULAR28, European League Against Rheumatism (28-joint count). aNonresponder imputation: missing ACR responses were imputed as nonresponder. P values are nominal without multiplicity adjustment, using Fisher's exact test. bObserved cases. P values are comparisons with placebo, using two-sided Wilcoxon rank-sum test. cEULAR28 response is classified as good, moderate, and no response based on the DAS28 ESR at week 24 and the DAS28 ESR improvement from baseline at week 24 [31].

Cardiel et al. Arthritis Research & Therapy 2010 12:R192   doi:10.1186/ar3163

Open Data